Centaurus Financial, Inc. Crispr Therapeutics Ag Transaction History

Centaurus Financial, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$53.19 - $79.24 $82,178 - $122,425	-1,545 Closed	0 $0
Q4 2021 Feb 01, 2022	SELL	$70.09 - $111.29 $35,045 - $55,645	-500 Reduced 24.45%	1,545 $117,000
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $22,040 - $31,327	200 Added 10.84%	2,045 $229,000
Q2 2021 Aug 10, 2021	SELL	$100.84 - $161.89 $20,168 - $32,377	-200 Reduced 9.78%	1,845 $299,000
Q1 2021 Apr 30, 2021	BUY	$110.72 - $210.04 $54,474 - $103,339	492 Added 31.68%	2,045 $249,000

Q4 2020 Jan 25, 2021	BUY	$79.67 - $173.23 $123,727 - $269,026	1,553 New	1,553 $238,000
Q3 2018 Nov 05, 2018	SELL	$44.35 - $65.71 $12,462 - $18,464	-281 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$42.62 - $73.59 $11,976 - $20,678	281 New	281 $17,000

549

56.3M

2.91M

2.47M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.14B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.